Endocrine Abstracts (2017) 49 EP1083 | DOI: 10.1530/endoabs.49.EP1083

Effects of male hypogonadism treatment on the bone mineral density

Mário Rui Mascarenhas1,2, Ana Paula Barbosa1,2, Ana Raquel Coelho Gomes2, Catarina Silvestre2, David Barbosa2, Raquel Paixão2, Carolina Faria2, Ana Sofia Osório2, Vânia Gomes2, Joana Ferreira1, Manuel Bicho1 & Maria João Bugalho2


1Endocrinology and Metabolic Diseases, Faculty Medicine of Lisbon, Lisbon, Portugal; 2Endocrinology, Diabetes and Metabolism Department, Santa University Maria Hospital-Chln, Epe, Lisbon, Portugal.


Increased recognition of the morbidity and mortality due to osteoporosis in men are main issues of public health. Ageing and the propensity to falls are the main risk factors for osteoporotic fractures in men; moreover, hypogonadism is an important secondary cause of low bone mineral density (BMD), but very little is known about the effect of hypogonadism treatment on the BMD.

Objective: The aim was to study the impact on BMD of the treatment of male hypogonadism.

Material and methods: A group of 26 men were devided in the hypogonadotrophic hypogonadism (n=17) and hypergonadotrophic hypogonadism (n=9) groups. The BMD at several skeletal sites (assessed by DXA scans) was evaluated before and during treatment (duration from 1 to 8 years, on average 3.1 (±2.3) years). Adequate statistical tests were used (statistical significance P<0.05).

Results: The treatment did not improved significantly the mean BMDs at several skeletal sites (Table 1). Moreover the BMDs were similar before and during the treatment in the hypergonadotrophic hypogonadism group; nevertheless, in the hypogonadotrophic hypogonadism group the mean BMDs were significantly higher at the lumbar spine, at the hip, at the forearm and at the whole body during therapy.

Conclusions: After more than three years of treatment there was no improvement on the BMD significantly in the total hypogonism group. The treatment of male hypogonadism has improved the BMD at several skeletal regions just in the hyponadotrophic group.

Table 1 BMD qualification in hypogonadism before and during therapy.
BMDHypogonadism before treatment n=26 (100%)Hypogonadism during treatment n=26 (100%)
Normal6 (23.1%)8 (30.8%)
Reduced12 (46.1%)11 (42.3%)
Osteoporosis8 (30.8%)7 (26.9%)